SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 16,
2010
Blonder
Tongue Laboratories, Inc.
(Exact
Name of registrant as specified in its charter)
Delaware 1-14120
52-1611421
(State
or other jurisdiction of
incorporation) (Commission
File
Number) (I.R.S.
Employer Identification No.)
One Jake
Brown Road, Old Bridge, New Jersey 08857
(Address if principal executive offices) (Zip
Code)
Registrant’s telephone number,
including area code: (732)
679-4000
Not
Applicable
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[_]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[_]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[_]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
[_]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
ITEM
5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF
DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN
OFFICERS.
(b) Departure
of Named Executive Officer
On February 16, 2010, Blonder Tongue
Laboratories, Inc. (the “Company”) advised Peter Daly, the Company’s Senior
Vice-President-Marketing and Sales and Chief Marketing Officer, that his
employment with the Company was being terminated, effective on such
date. Mr. Daly’s position was eliminated in connection with the
Company’s efforts to further streamline its organizational structure and reduce
managerial costs. Sales
responsibilities previously assigned to Mr. Daly will be assumed by other senior
members of the Company’s Sales Department. Mr. Daly’s marketing and
other responsibilities will be assumed by members of the Company’s senior
management team.
(e) Executive
Compensation Arrangement
In connection with the termination of
Mr. Daly’s employment with the Company, Mr. Daly’s compensation arrangement, as
previously disclosed on the Company’s Current Report on Form 8-K filed on
October 9, 2009, was terminated effective as of February 16, 2010.
Mr. Daly is eligible for severance
payments in accordance with the Company’s standard severance policies for
eligible employees whose employment is involuntarily terminated. Mr.
Daly will receive six (6) weeks of severance calculated at one week of pro-rated
base salary for each year of service to the Company, payment by the Company of
its standard contribution toward Mr. Daly’s continuing group heath insurance
coverage for the same period, and payment of all unused vacation
time.
2
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
BLONDER
TONGUE LABORATORIES, INC.
By: /s/ Eric
Skolnik
Eric Skolnik
Senior
Vice President and Chief Financial Officer
Date:
February 19, 2010
3